One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
22nd Century Group logo
22nd Century Group XXII
$ 0.09 -56.75%
report update icon

Quarterly report 2026-Q1
added 05-07-2026

22nd Century Group Income Statement 2025-2009 | XXII

Brief overview of financial results at 22nd Century Group

The comparison covers a five-year financial horizon. Revenue reported by 22nd Century Group was $28.1 million at the beginning of the period and $17.6 million at the end. Overall revenue changed by −37.4%, equal to an annualized rate of about −9%. The negative rate indicates weakening core operations.

The five-year change in gross profit reached +414.7%: from $1.4 million to $7.4 million. Cost of revenue developed more favorably than sales, supporting gross profitability. The gross margin was 5.1% at the start and 42.1% at the end. Improving gross profitability strengthens the quality of revenue growth.

EBITDA changed from −17.7 million dollars to −11.1 million dollars (+37.2%). Additional revenue translated efficiently into EBITDA. Comparing the endpoints gives EBITDA margins of −62.8% and −63%. EBITDA as a share of revenue remained steady.

The final result was −19.7 million dollars initially and −5.1 million dollars in the final year. The loss narrowed, although sustainable profitability has not yet returned.

The market value of the business moved from 347 million dollars to 541 thousand dollars, or −99.8%. The market is not yet fully reflecting the fundamental progress.

Conclusion

The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on consistent operating efficiency, improving gross profitability and net-income growth. The overall view is constrained by a weaker market valuation, a low EBITDA margin and weak sales momentum. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement 22nd Century Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

541 K 1.64 K 1.14 K 11.4 M 483 M 347 M 124 M 290 M 355 M 73.5 M 85.2 M 70.2 M 115 M 26.2 M 14.5 M - -

Shares

184 K 557 9.47 K 12.9 M 156 M 139 M 126 M 124 M 101 M 79.8 M 68.1 M 60 M 43.6 M 30.4 M 26.4 M 12.4 M -

Historical Prices

2.94 2.94 0.12 0.89 3.09 2.2 1.1 2.49 2.8 1.09 1.4 1.65 2.14 0.75 0.42 - -

Net Income

-5.05 M -15.2 M -141 M -59.8 M -5.03 M -19.7 M -26.6 M -7.97 M -13 M -11.6 M -11 M -15.6 M -26.2 M -6.74 M -1.35 M -1.42 M -

Revenue

17.6 M 24.4 M 7.36 M 9.95 M 6.81 M 28.1 M 25.8 M 26.4 M 16.6 M 12.3 M 8.52 M 529 K 7.28 M 18.8 K 1.01 M 49.8 K -

Cost of Revenue

10.2 M 14.3 M 24.9 M 38.7 M 29.5 M 26.7 M 25.8 M 25.5 M 17.3 M 12.7 M 9.1 M 498 K 462 K 68 K - - -

Gross Profit

- - - - - 1.44 M 14.5 K 899 K -708 K -430 K -581 K 30.6 K 6.82 M -49.2 K 594 K - -

Operating Income

-11.6 M -14 M -44.9 M -33.6 M -28.4 M -19.2 M -23.6 M -24 M -13.3 M -11.4 M -12 M -11.8 M 1.81 M -3.24 M -3.76 M -1.1 M -

Interest Expense

-207 K 507 K 9.37 M 55 K 58 K 72 K 56 K 11 K 29.1 K 37.7 K 53 K 7.09 K 749 K - - - -

EBITDA

-11.1 M -13.4 M -44.1 M -30.8 M -27.2 M -17.7 M -21 M -22.7 M -12.4 M -10.5 M -11.4 M -11.3 M 1.96 M -3.05 M -3.58 M -933 K -

Operating Expenses

8.43 M 11.6 M 36.2 M 35.5 M 29.9 M 20.4 M 22.4 M 24.9 M 12.6 M 11 M 11.5 M 11.8 M 5 M 3.19 M 4.35 M - -

General and Administrative Expenses

7.59 M 10.3 M 31.1 M 32.2 M 25.9 M 15 M - 7.66 M 7.12 M 6.19 M 7.76 M 8.79 M 4.11 M 2.21 M 1.79 M 591 K -

All numbers in USD currency

Quarterly Income Statement 22nd Century Group

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

595 K 3.54 M 250 K 1.73 M 31.7 K 4.22 K 2.62 K 23.6 K 2.72 M 1.21 M 878 K 846 K 14.3 M 14 M 12.1 M 163 M 163 M 163 M 155 M 144 M 139 M 139 M 139 M 139 M 138 M 125 M 125 M 125 M 125 M 124 M 124 M 124 M 124 M 101 M 91.6 M 90.7 M 90.7 M 80.4 M 76 M 74 M 71 M 70.8 M 66.6 M 64.2 M 64.1 M 60.1 M 58.7 M 57.6 M 56.9 M 47.4 M 39.8 M 36.3 M 34.3 M 31 M 29.3 M 28 M 27.2 M 27.2 M 27.2 M 23.9 M

Net Income

-3.26 M 5.49 M -3.41 M -4.33 M - -3.76 M -1.11 M -5.74 M - -72.7 M -20.5 M -18.2 M - -13.1 M -11.5 M -8.92 M - -9.44 M -4.17 M -5.03 M -6.4 M -4.22 M -5.06 M -4.03 M -6.2 M -10.2 M -8.04 M -2.07 M -8.92 M 6.3 M -6.74 M 1.39 M -3.74 M -3.32 M -3.36 M -2.62 M -2.75 M -2.68 M -2.9 M -3.25 M -2.86 M -2.76 M -1.29 M -4.12 M -5.59 M -2.72 M -1.97 M -5.32 M - -15.4 M -446 K -2.51 M - -449 K 142 K -2.12 M - -465 K -1.1 M -649 K

Revenue

4.1 M 4.01 M 4.08 M 5.96 M - 5.95 M 7.95 M 6.47 M - 7.87 M 8.05 M 8.93 M - 19.4 M 14.5 M 9.04 M - 7.81 M 8.37 M 6.81 M 7.31 M 7.31 M 6.44 M 7.06 M 7.26 M 6.46 M 5.81 M 6.29 M 7.13 M 6.26 M 6.91 M 6.12 M 5.94 M 4.53 M 3.9 M 2.23 M 3.34 M 3.1 M 2.83 M 3.02 M 2.93 M 2.67 M 2.31 M 616 K 911 64.4 K 16.1 K 448 K - 52.5 K - - - 15.7 K - - - 529 K 155 K 117 K

Cost of Revenue

1.92 M 2.56 M 2.86 M 2.88 M - 3.1 M 3.87 M 4.21 M - 3.92 M 4.68 M 4.72 M - 18.8 M 13.6 M 8.74 M - 7.52 M 7.92 M 6.16 M - 6.95 M 6.23 M 6.77 M - 6.48 M 5.9 M 6.4 M - 6.11 M 6.75 M 6.04 M - 4.87 M 4.06 M - - - - - - 2.95 M - - - 306 K - - - 20.6 K - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - 287 K 225 K -21.1 K -86.3 K -103 K 515 K 151 K 162 K 71.6 K 71.4 K -340 K -165 K -274 K -228 K -185 K -141 K 124 K 10.8 K -281 K -293 K -16.4 K -806 -241 K 2.94 K 270 K - 32 K - - - - - - - - - -

Operating Income

-3.04 M -3.21 M -2.98 M -2.57 M - -3.38 M -2.05 M -4.43 M - -8.25 M -12 M -10.4 M - -15.3 M -10.5 M -8.15 M - -7.57 M -6.64 M -5.17 M -6.25 M -4.04 M -4.75 M -4.14 M -5.55 M -7.61 M -5.03 M -5.38 M -5.8 M -6.21 M -7.04 M -4.97 M -3.77 M -3.27 M -3.28 M -2.97 M -2.73 M -2.6 M -2.83 M -3.23 M -2.83 M -2.75 M -2.35 M -4.12 M -5.72 M -2.82 M -2.04 M -1.19 M - -1.09 M -1.62 M -1.39 M - -633 K -1.37 M -447 K - -766 K -1.09 M -638 K

Interest Expense

-162 K -33 K -12 K -162 K - 100 K 339 K 1.02 M - 1.27 M -613 K 328 K - 148 K 77 K 5 K - 23 K 14 K 7 K - 23 K 19 K 12 K - 12 K 13 K 11 K - 4.43 K - - - 6.98 K 7.64 K 7.92 K - 9.32 K 9.32 K 10.4 K - 8.7 K 13.8 K 5.51 K - 1.79 K 1.77 K 1.75 K - - - - - - - - - - - -

EBITDA

-2.93 M -3.09 M -2.86 M -2.47 M - -3.23 M -1.9 M -4.33 M - -8.08 M -11.9 M -10.2 M - -15.1 M -10.3 M -7.98 M - -7.4 M -6.49 M -5.03 M -6.25 M -3.88 M -4.6 M -3.87 M -5.55 M -7.45 M -4.88 M -5.09 M -5.8 M -5.35 M -6.5 M -4.7 M -3.77 M -2.65 M -2.87 M -2.77 M -2.73 M -2.05 M -2.47 M -3.05 M -2.83 M -2.25 M -2.02 M -3.96 M -5.72 M -2.5 M -1.84 M -1.12 M - -914 K -1.57 M -1.34 M - -582 K -1.32 M -401 K - -721 K -1.04 M -594 K

Operating Expenses

2.4 M 2.15 M 2.35 M 1.96 M - 2.79 M 2.62 M 3.3 M - 8.33 M 11.1 M 10.4 M - 15.9 M 11.4 M 8.46 M - 7.86 M 7.09 M 5.82 M - 4.4 M 4.95 M 4.43 M - 7.58 M 4.94 M 5.28 M - 6.36 M 7.2 M 5.04 M - 2.93 M 3.12 M 2.7 M - 2.41 M 2.69 M 3.35 M - 2.48 M 2.06 M 4.11 M - 2.58 M 2.04 M - - - - - - - - - - - - -

General and Administrative Expenses

2.12 M 1.85 M 2.12 M 1.8 M - 2.55 M 2.36 M 2.91 M - 6.94 M 10.3 M 9.84 M - 14.5 M 8.68 M 7.26 M - 6.83 M 6.18 M 4.83 M - 3.17 M 3.5 M 3.14 M - 4.06 M 2.37 M 2.24 M - 1.76 M 1.91 M 2.03 M - 1.64 M 1.81 M 1.62 M - 1.23 M 1.72 M 1.85 M - 1.3 M 1.3 M 3.65 M - 1.81 M 1.34 M 1.01 M - 908 K 1.4 M 1.15 M - 370 K 1.05 M 310 K - 451 K 604 K 326 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company 22nd Century Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.05 -1.85 % $ 6.61 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.99 0.69 % $ 99.3 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.16 2.88 % $ 3.63 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 59.01 1.7 % $ 7.89 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 55.56 -0.7 % $ 10.7 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 29.4 0.5 % $ 1.95 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.78 3.0 % $ 46.1 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 2.34 14.46 % $ 5.46 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.49 -2.55 % $ 196 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 22.07 -1.6 % $ 1.27 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 25.29 1.0 % $ 1.5 B usaUSA
Xencor Xencor
XNCR
$ 29.85 18.55 % $ 2.22 B usaUSA
Annexon Annexon
ANNX
$ 3.71 -1.18 % $ 575 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.77 -0.56 % $ 2.91 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 113.32 -2.07 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 12.44 1.3 % $ 15 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.17 -0.43 % $ 738 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 513.55 -1.98 % $ 131 B usaUSA
Altimmune Altimmune
ALT
$ 2.07 -2.36 % $ 182 M usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 9.85 0.1 % $ 270 M israelIsrael
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 31.72 1.67 % $ 4.04 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 19.86 0.1 % $ 223 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.14 -2.99 % $ 61.2 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.58 1.36 % $ 287 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 245.73 0.97 % $ 14.9 B danmarkDanmark
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA